Background: Hepatitis C virus (HCV) is one of the major globally cause of death and morbidity. The appearance of direct-acting antiviral agents (DAAs), which specifically target HCV proteins, has provided insights into the current situation Ceruloplasmin (Cp), where its serum levels tend to be high in myocardial infarction, neoplastic and inflammatory conditions. Objective: The aim of the current work was to evaluate the prognostic value of serum ceruloplasmin in chronic hepatitis C before and after treatment by direct-acting antiviral agents and possibility of using it as a marker for hepatitis C virus treatment response. Patients and methods: This intervention prospective study was conducted on one hundred subjects attending at the Hepatology Clinic at the Hepatology Clinic at Algalaa Military Hospital and Kopri Elkopa Military Hospital and Al-Hussein university Hospital, from December 2016 till June 2017. The associations between serum Ceruloplasmin levels in chronic HCV patients before receiving DAAS and three months after was investigated. Results: showed that serum Ceruloplasmin levels were slightly higher after receiving DAAS and so it can be used as a marker for responsiveness to direct acting antiviral drugs. Conclusion: It could be concluded that ceruloplasmin can be used as a marker for responsiveness to direct acting antiviral drugs